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Abstract
Background: Coronary angiography (CAG) is widely used to assess lumen dimensions, and optical coherence
tomography (OCT) is used to evaluate the characteristics of atherosclerotic plaque. This study was aimed to
compare coronary lumen dimensions using CAG and plaque characteristics using OCT and their changes during
statin therapy.
Methods: We identified 97 lipid-rich plaques from 69 statin-naïve patients, who received statin therapy in the
following 12 months. CAG and OCT examinations were conducted at baseline and 12-month follow-up period.
Results: Lesion length, as measured by CAG, was closely correlated with lipid length by OCT (baseline: r = 0.754,
p < 0.001; follow-up: r = 0.639, p < 0.001). However, no significant correlations were found between the other
findings on OCT and data on CAG. With 12-month statin therapy, microstructures of lipid-rich plaques were
significantly improved, but CAG-derived lumen dimensions were not improved. Moreover, we found no significant
relationship between changes in OCT measurements and changes in CAG data over time.
Conclusion: Lipid length on OCT and lesion length on CAG were closely correlated. However, plaque
microstructural characteristics on OCT showed no significantly statistically correlations with lumen dimensions on
CAG, neither did their evolutionary changes induced by statin over time.
A retrospectively registered study: Clinical trial registry: ClinicalTrial.gov. Registered number: NCT01023607.
Registered 1 December 2009.
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Background
Patients with rupture-prone lesions in the coronary ar-
teries, also known as “vulnerable plaques”, are at risk of
acute coronary syndrome (ACS) [1, 2]. Morphological
characteristics of vulnerable plaques tend to possess a
large lipid core and a thin fibrous cap overlying
inflammatory-cell infiltration [3, 4]. Statin-based lipid-
modulating therapy has been documented to stabilize
vulnerable plaque and reduce atheroma volume [5–7].
Catheter-based diagnostic techniques, such as coronary
angiography (CAG), optical coherence tomography
(OCT) and intravascular ultrasound (IVUS), provide
more accurate histopathological characteristics of coron-
ary lesions and are widely applied in clinical examination
of coronary arteries before or after percutaneous coron-
ary interventions and as adjunctive devices to assess
lesion characteristics or lumen and stent situations in
detail [8–10]. OCT, with a high resolution of approxi-
mately 10―20 μm, allows for the assessment of the mi-
crostructures in plaques and has recently been regarded
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as an “optical biopsy” imaging modality that can
visualize the morphological characteristics and composi-
tions of plaques in situ and in real time [4, 11–13]. It is
generally known that CAG is widely used to assess
lumen dimensions, and display the lumen as a longitu-
dinal and cross-sectional silhouette [14–16]. The current
study was aimed to identify the relationship between
lumen dimensions as seen on CAG and plaque micro-
structures as seen on OCT, and the relationship between
their changes during statin intervention.
Methods
Study population
This was a retrospective study of a single blind and ran-
domized clinical trial registry (ClinicalTrial.gov registered
number: NCT01023607), designed to assess the effects of
statins on lipid-rich plaques. The inclusion criteria were as
follows: 1) were statin-naïve (i.e., those who were not on
statins) patients with one or more mild-to-moderate le-
sion(s); 2) had non-culprit lesions identified as lipid-rich
plaques by OCT; 3) were to receive statin treatment
during the following 12–month follow-up period; and 4)
were to undergo CAG and three-vessel OCT imaging
procedures during the 12–month follow-up period. The
exclusion criteria were as follows: 1) a life expectancy
≤12 months; 2) contraindications to oral statins; 3) severe
hepatic or renal dysfunction; or 4) congestive heart failure.
Fifty-one patients including those who didn’t have the
follow-up information (n = 31), had poor-quality images
from OCTs (n = 13), and mismatched imaging (n = 7)
were excluded. After screening, 69 patients (62.3% male;
age: 55.7 ± 9.4 years) with 97 coronary non-culprit, lipid-
rich plaques (30.1% located in the left anterior descending
artery, 46.6% in right coronary artery, 17.5% in left
circumflex artery) were analyzed in the current study. This
study was approved by the institutional review board of
the Second Hospital of Harbin Medical University
(Harbin, China), and all patients provided written
informed consent before any procedures were initiated.
Angiographic and OCT images follow-up
According to the study protocol, follow-up angiography
and three-vessel OCT images were performed at base-
line and 12 months. Quantitative angiographic of the
coronary arteries was performed to determine the min-
imal lumen diameter (MLD), diameter stenosis (DS) and
lesion length as previously described in detail [17]. The
interpreter was blinded to OCT findings. Analyses of the
baseline and follow-up coronary angiograms were con-
ducted using the Cardiovascular Angiography Analysis
System (CAAS 5.10, Pie Medical Imaging B.V.,
Maastricht, the Netherlands).
After detecting by CAG and dealing with the culprit/tar-
get lesions, intracoronary OCT images were performed as
previously described [4, 5]. In short, with the TD OCT sys-
tem, a 3-F occlusion balloon catheter was advanced prox-
imal to the lesion and inflated at 0.5 atm. to 0.7 atm.
During image acquisition, lactate Ringer’s solution was in-
fused intra-coronary from the distal tip of the occlusion
balloon catheter at 0.5 ml/s to 2.0 ml/s by a high-pressure
injector. The OCT wire was pulled back from a distal to a
proximal position automatically at a rate of 1.0 mm/s. The
fibrous-cap thickness (FCT) was measured 3 times at the
thinnest place, and the values were averaged. A lipid-rich
plaque was defined as previously that plaque with fibrous-
cap thickness < 120 μm and lipid arc > 100° [5]. In lipid-
rich plaque, the lipid arc was measured at 1 mm interval,
the maximum value was recorded as maximum lipid arc,
and the mean value was calculated as mean lipid arc. Lipid
length was measured on a longitudinal view. Lipid index,
was calculated as the mean lipid arc multiplied by lipid
length [18]. A thin-cap fibroatheroma (TCFA) has rich
lipid core and FCT < 65 μm, while a thick-cap fibroather-
oma (ThCFA) was a LRP with a thick fibrous cap
(≥65 μm) [3, 19]. Macrophage accumulation was character-
ized as increased signal intensity, combined with heteroge-
neous backward shadows within the lesion. Microvessel,
also named neovascularization, appears as signal-free tubu-
loluminal structure with a diameter of 50–300 μm that was
observed as ≥ 3 consecutive cross-sectional OCT images
[20]. Beside lipid pool, the thin and linear region of high in-
tensity was cholesterol crystal [21]. Intraluminal thrombus
was identified as protruding masses attached to the arterial
wall [22]. Calcification was recorded when an area showed
low backscatter signal and a sharply delineated border.
Plaque disruption was a discontinued fibrous membrane
with underlying communication between the lumen and
the cavity.
All OCT images were analyzed using proprietary offline
software (LightLab Imaging, Inc., Westford, MA, USA) by
two independent, experienced observers. In cases in which
was disagreement between them, a third independent in-
vestigator helped reach a consensus on image matching
and quality. All investigators of CAG and OCT images
were blinded to the patient’s conditions and the study
protocol, and all images were digitally stored for future
analyses. In the follow up studies, repeated measurements
from the same reference points were performed, and the
measurements of CAG and OCT between the two points
were determined using computer software.
Statistical analysis
All statistical analysis was performed by an independent
statistician using IBM SPSS version 17.0 (SPSS Inc., Chicago,
Illinois, USA). Data are expressed as mean ± standard devi-
ation (SD) or counts and proportions. Quantitative data at
baseline and at follow-up are compared using paired t test
and qualitative data using McNemar test. Continuous
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variables between TCFAs and ThCFAs were compared by
using unpaired t test. The categorical variables were ana-
lyzed using the Chi-square or Fisher exact test. Pearson or
Spearman ranks test was used to investigate the relationship
between CAG findings and OCT measurements, and also
the correlations between changes in CAG and changes in
OCT measurements. A p-value < 0.05 was considered to be
statistically significant.
Results
The baseline clinical characteristics of the patients are
shown in Table 1. As shown in Table 2, with statin treat-
ment, the level of low-density lipoprotein cholesterol (LDL-
C) was decreased by 25.4% (from 109.4 ± 24.6 mg/dL base-
line to 73.9 ± 29.2 mg/dL follow-up, p < 0.001). In addition,
except for high-density lipoprotein cholesterol (HDL-C), the
total cholesterol, triglycerides, and apolipoprotein B were all
markedly improved (p < 0.001, p < 0.001, p < 0.001, p =
0.005, respectively).
The lesion measurements done using CAG and OCT at
baseline and follow-up are shown in Table 2. With statin
therapy for 12 months, fibrous-cap thickness increased
from 61.1 ± 18.5 μm to 159.1 ± 78.9 μm (p < 0.001); max-
imum lipid arc, mean lipid arc and lipid index significantly
decreased (p < 0.001, all). In addition, we found that lesion
length on CAG slightly increased (from 11.3 ± 5.1 mm
baseline to 11.7 ± 5.0 mm follow-up, p = 0.069), but OCT
showed that lipid length significantly decreased (from 9.9 ±
4.7 mm to 9.3 ± 4.9 mm, p = 0.01). Moreover, the OCT
qualitative measurements showed that the prevalence
of TCFA, macrophage infiltration, microvessels, and
cholesterol crystals were significantly reduced at
follow-up (p < 0.001, p = 0.048, p = 0.022, p = 0.031,
p = 0.015, and p = 0.003, respectively), with the ex-
ception of the presence of calcification (p = 0.868).
However, lumen dimensions as measured by CAG,
including minimal lumen diameter and diameter stenosis
(MLD: from baseline 2.0 ± 0.5 mm to follow-up 2.0 ±
0.5 mm, p = 0.824; DS: from 28.9 ± 10.5% to 29.5 ± 11.1,
p = 0.53), were not significantly improved.
The correlations between the CAG and OCT findings
of coronary lipid-rich plaques at baseline and also at
follow-up were summarized in Table 3. The lesion
longitudinal silhouette data showed that the whole
length of plaque (lesion length) on CAG and the length
of lipid pool on OCT were closely related at any single
time points (r = 0.754, p < 0.001 at baseline; r =
0.639, p < 0.001 at follow-up); the lesion length also
positively correlated with the lipid index. Moreover,
diameter stenosis on CAG was significantly correlated
with maximum lipid arc on OCT at baseline only (r =
0.209, p = 0.041). Minimal lumen diameter was not found
significantly correlated with OCT measurements at any
single time points.
As shown in Table 4, the correlations between the
changes in CAG and changes in OCT quantitative data
from baseline to follow-up were analyzed. Change in
minimal lumen diameter from baseline to follow-up was
not significantly correlated with any changes in OCT
quantitative data; neither was the change in diameter
stenosis. And no significant correlations were found be-
tween change in lesion length on CAG and change in
lipid length on OCT.
According to the FCT at baseline, plaques were classi-
fied into TCFAs (thin-cap fibroatheromas, fibrous-cap
thickness < 65 μm) and ThCFAs (thick-cap fibroathero-
mas, fibrous-cap thickness ≥ 65 μm). Comparisons of le-
sion characteristics between TCFAs and ThCFAs were
summarized in Table 5. Fibrous-cap thickness in both
groups markedly increased (p < 0.001 both); and the
maximum lipid arc of TCFAs, but not that of ThCFAs,
significantly decreased over time. Diameter stenosis of
TCFAs had a mean increase of 3.86% (p = 0.014) from
the baseline to the 12-month follow-up; while DS of
ThCFAs had a mean decrease of 1.14% (p = 0.26) over
Table 1 Baseline clinical characteristics
Baseline characteristics
Patients number n = 69





Previous MI 15 (21.7)
Prior PCI 12 (17.4)
ACS 55 (79.7)
SAP 14 (20.3)
Concomitant drugs at follow-up:
ACEI/ARB 31 (44.9)






Plaques numbers n = 97
Left Anterior Descending 31 (30.1)
Right Coronary Artery 48 (46.6)
Left Circumflex 18 (17.5)
Data were presented as mean ± standard deviation (SD) or number (%) except
for SD. ACEI angiotensin-converting enzyme inhibitor, ACS acute coronary
syndrome, ARB angiotensin II receptor blocker, CCB calcium channel blocker,
SAP stable angina pectoris, Previous MI, previous myocardial infarction, Prior
PCI prior percutaneous coronary intervention
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the same period. In addition, the mean lipid length sig-
nificantly decreased over time (TCFAs: −1.1 mm, p =
0.005; ThCFAs: −0.40 mm, p = 0.218); however, the
mean value of lesion length did not significantly change.
Given the above, both TCFAs and ThCFAs showed sig-
nificant improvements in lesion microstructures, but DS
of ThCFAs grew narrower over time; although the lesion
length of ThCFAs did not decreased at follow-up, the
lipid length inside the lesion was significantly reduced.
These results suggested that the lipid core decreased less
and diameter stenosis increased in ThCFAs over time.
As shown in Figs. 1 and 2, lipid-rich plaques were also
classified according to OCT-derived plaque types, such
as the existence of a thin-cap < 65 μm, macrophage infil-
tration, microvessels, or cholesterol crystals. The differ-
ences between TCFAs and ThCFAs were described
above. In addition, no significant differences of cross-
sectional variables were observed on CAG measure-
ments regardless of whether the lesions contained
macrophage infiltration, microvessels, or cholesterol
crystals.
Discussion
To our knowledge, this is the first study to compare cor-
onary lumen dimensions and plaque microstructural
characteristics, and their progression during statin ther-
apy using quantitative angiography and OCT imaging.
The major results can be summarized as follows: 1) lipid
length (OCT) was closely correlated with lesion length
(CAG), but the other measurements on OCT and find-
ings on CAG of non-culprit lipid-rich plaques were not
significantly correlated; 2) although the microstructures
were improved significantly at follow-up, the longitu-
dinal and cross-sectional silhouette of the coronary le-
sions were not significantly improved; 3) compared with
TCFAs, ThCFAs had a less decrease in the lipid index;
ThCFAs had an increase in diameter stenosis at follow-
up; 4) with 12-month statin therapy, no significant
Table 2 Serum lipid results, CAG and OCT measurements at baseline and follow-up
Variables Baseline Follow-up p-value
Serum lipid
Total cholesterol, mg/dl 198.6 ± 42.2 146.1 ± 40.0 <0.001
LDL-C, mg/dl 109.4 ± 24.6 73.9 ± 29.2 <0.001
HDL-C, mg/dl 49.3 ± 12.3 46.7 ± 13.9 0.123
LDL-C/HDL-C 2.3 ± 0.8 1.7 ± 0.7 <0.001
Triglycerides, mg/dl 215.7 ± 151.7 140.2 ± 64.3 <0.001
Apolipoprotein B, mg/dl 89.0 ± 24.1 63.3 ± 25.2 <0.001
OCT quantitative data
Fibrous-cap thickness, μm 61.1 ± 18.5 159.1 ± 78.9 <0.001
Maximum lipid arc, ° 241.2 ± 69.9 206.4 ± 75.3 <0.001
Mean lipid arc, ° 174.8 ± 51.6 152.5 ± 55.7 <0.001
Lipid length, mm 9.9 ± 4.7 9.3 ± 4.9 0.010
Lipid index 1783.4 ± 1038.7 1476.0 ± 1042.7 <0.001
OCT qualitative data, n (%)
TCFA 63 (64.9%) 13 (13.4%) <0.001
Macrophage 71 (73.2%) 58 (59.8) 0.019
Micro-vessel 44 (45.4) 29 (29.9) 0.004
Cholesterol crystal 23 (23.7) 10 (10.3) 0.002
Thrombus 6 (6.2) 0 N/A
Spotty calcification 25 (26.0) 24 (24.7) 1.000
Disruption 9 (9.3) 0 N/A
CAG quantitative data
Minimal lumen diameter, mm 2.0 ± 0.5 2.0 ± 0.5 0.824
Diameter stenosis, % 28.9 ± 10.5 29.5 ± 11.1 0.530
Lesion length, mm 11.3 ± 5.1 11.7 ± 5.0 0.069
Data are presented as mean ± SD or n (%). Quantitative data at baseline and at follow-up are compared using paired t test and qualitative data using McNemar
test. CAG coronary Angiography, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, OCT optical coherence tomography, TCFAs
thin-cap fibroatheromas; N/A not applicable. A p-value < 0.05 was considered statistically significant. ° arc of lipid content.
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correlations between changes in CAG findings and
changes in OCT measurements were observed.
It is generally known that the true architecture of the ar-
terial wall and inside the atherosclerotic cannot be
visualized directly using CAG, which is good at depicting
the lumen as a longitudinal and cross-sectional silhouette
[15, 23]. OCT, with its high-resolution histological images,
has the capacity to delineate microstructural characteris-
tics of atherosclerotic plaques, such as FCT, inflammation,
and intra-plaque neovascularization [10, 13, 24]. However,
so far, limited researches have been performed to explore
correlations between CAG and OCT measurements on
coronary atherosclerotic plaque. FCT and lipid burden are
incontrovertible crucial factors for the rupture of lipid ath-
erosclerotic plaque [12, 25]. The intravascular modality
validated by OCTassessment and histological examination
of the fibrous-cap thickness were highly consistent [26],
while CAG had limitations to evaluate the microstructures
and vulnerability of plaque [15, 24, 27]. Even so, in this
study, we found a statistically significant but weak correl-
ation between diameter stenosis by the standard method
of evaluating lumen dimension with CAG and the max-
imum lipid arc with OCT at baseline but not at follow-up.
However, if the follow-up duration of statin intervention
Table 3 Correlations between the CAG and OCT data at single time points
CAG data OCT data Correlation p-value
Baseline
Minimal lumen diameter, mm Fibrous-cap thickness, μm −0.004 0.971
Maximum lipid arc, ° 0.062 0.545
Mean lipid arc, ° 0.071 0.494
Lipid length, mm 0.134 0.197
Lipid index 0.133 0.200
Diameter stenosis, % Fibrous-cap thickness, μm −0.169 0.099
Maximum lipid arc, ° 0.209 0.041
Mean lipid arc, ° 0.105 0.308
Lipid length, mm 0.099 0.341
Lipid index 0.115 0.265
Lesion length, mm Fibrous-cap thickness, μm −0.248 0.014
Maximum lipid arc, ° −0.303 0.003
Mean lipid arc, ° 0.148 0.149
Lipid length, mm 0.754 <0.001
Lipid index 0.648 <0.001
Follow-up
Minimal lumen diameter, mm Fibrous-cap thickness, μm −0.076 0.458
Maximum lipid arc, ° 0.086 0.410
Mean lipid arc, ° 0.087 0.433
Lipid length, mm 0.104 0.334
Lipid index 0.099 0.372
Diameter stenosis, % Fibrous-cap thickness, μm 0.018 0.870
Maximum lipid arc, ° −0.041 0.712
Mean lipid arc, ° −0.014 0.902
Lipid length, mm 0.072 0.506
Lipid index 0.065 0.561
Lesion length, mm Fibrous-cap thickness, μm −0.112 0.300
Maximum lipid arc, ° 0.176 0.107
Mean lipid arc, ° 0.125 0.261
Lipid length, mm 0.639 <0.001
Lipid index 0.527 <0.001
Correlations between the CAG data and OCT data were analyzed by Pearson or Spearman ranks test. A p-value < 0.05 was considered statistically significant. ° arc
of lipid content. ° arc of lipid content.
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is long enough, good correlations might be observed be-
tween OCT measurements and CAG findings on coronary
plaques.
There were other important discoveries from this
study. Lipid length seen on OCT results was strongly
correlated with lesion length, but the correlation was
weaker after 12 months of statin therapy. The weakened
correlation might because statin therapy induces lipid
core inside the lesion to shrink; however, lesion length
was not significantly reduced at follow-up. In addition,
the lipid index and microstructures of the lipid-rich pla-
ques were markedly improved by follow-up time, but the
luminal outline seen by CAG were not. These results are
consistent with and extend those of previous studies
documenting that CAG alone underestimates the com-
position of atherosclerosis and cannot evaluate the pres-
ence and magnitude of plaque microstructure
progression [23, 24]. Intravascular OCT provides in-
sights into plaque microstructures, which is needed in
lipid-rich plaque progression/regression evaluation.
Table 4 Correlations between changes in CAG findings and


















































Change in Lipid index −0.031 0.901
Correlations between changes in CAG findings and changes in OCT measurements
were analyzed by Pearson or Spearman ranks test. A p-value < 0.05 was considered
statistically significant
Table 5 Comparison of TCFAs and ThCFAs at baseline, at
follow-up and changes over time
TCFA (n = 63) ThCFA (n = 34) p-value
OCT measurements
Fibrous-cap thickness, μm
Baseline 49.8 ± 8.3 81.9 ± 13.4 <0.001
Follow-up 144.3 ± 80.9 186.4 ± 68.0 0.011
p-value <0.001 <0.001
Change 94.5 ± 79.8 104.5 ± 65.4 0.593
Maximum lipid arc, °
Baseline 261.2 ± 66.6 204.7 ± 61.4 <0.001
Follow-up 219.4 ± 74.8 182.8 ± 71.3 0.022
p-value <0.001 0.091
Change −41.8 ± 50.6 −22.0 ± 45.8 0.060
Mean lipid arc, °
Baseline 190.8 ± 50.6 145.7 ± 39.7 <0.001
Follow-up 160.6 ± 56.9 137.6 ± 50.9 0.052
p-value <0.001 <0.008
Change −30.3 ± 34.6 −8.1 ± 27.6 0.002
Lipid length, mm
Baseline 10.7 ± 4.9 8.4 ± 4.0 0.019
Follow-up 10.4 ± 5.1 7.3 ± 3.7 0.003
p-value 0.218 0.005
Change −0.4 ± 2.3 −1.1 ± 2.0 0.142
Lipid index
Baseline 2037.0 ± 1031.7 1083.6 ± 630.2 <0.001
Follow-up 1727.9 ± 1108.6 947.0 ± 705.9 <0.001
p-value <0.001 0.007
Change 309.1 ± 494.4 −136.6 ± 304.7 0.036
CAG measurements
Minimal lumen diameter, mm
Baseline 2.01 ± 0.58 1.99 ± 0.55 0.627
Follow-up 1.99 ± 0.55 1.98 ± 0.53 0.938
p-value 0.52 0.559
Change −0.02 ± 0.28 0.02 ± 0.24 0.686
Diameter stenosis, %
Baseline 30.7 ± 10.2 23.8 ± 9.4 0.021
Follow-up 29.5 ± 10.9 27.7 ± 10.7 0.878
p-value 0.26 0.014
Change −1.14 ± 8.08 3.86 ± 8.55 0.008
Lesion length, mm
Baseline 12.3 ± 5.6 9.37 ± 3.29 0.001
Follow-up 12.5 ± 5.4 9.98 ± 3.69 0.001
p-value 0.37 0.155
Change 0.24 ± 1.88 0.61 ± 2.18 0.788
Data are presented as mean ± SD. Data at baseline and at follow-up are compared
using paired t test; data between TCFAs and ThCFAs were compared by using
unpaired t test. TCFAs, thin-cap fibroatheromas (FCT < 65 μm); ThCFAs, thick-cap
fibroatheromas (FCT ≥ 65 μm). ° arc of lipid content.
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In the present study, we found that the changes in lumen
dimension were not significantly correlated with changes in
fibrous-cap thickness, neither with changes in lipid core
content. In another analysis on evaluating coronary plaque
progression/regression by OCT and IVUS, no significant
correlations were found between changes in OCT parame-
ters and changes in IVUS measurements [10].
The 12-month statin treatment has been reported to
induce lipid-rich plaque stabilization, such as continu-
ously thickening the fibrous cap and decreasing the
presence of macrophage infiltration; however, the plaque
volume determined by intravascular ultrasonography
(IVUS) was not reduced [5], and the cross-sectional lumen
architecture of coronary lesions were not significantly im-
proved. This is most likely because statin induces fibrous-
cap thickness of vulnerable plaques increasing, but the
lipid core under the fibrous cap shrinking. Significant
changes in atheroma volume and lumen dimensions can-
not be discovered if follow-up time or the duration of sta-
tin treatment is too short. Results of SATURN trial using
IVUS showed that maximal doses of statin-based lipid-
lowering treatment for 104 weeks induced regression of
atheroma volume [6]. Accordingly, the reduced vulnerabil-
ity of lipid-rich plaques most likely occurs earlier than im-
provements in plaque volume and lumen dimensions
during statin therapy; therefore, perennial statin-based
lipid-modulating therapy and a long-term follow-up are
necessary to attain the benefits of statins on decreased
plaque volume and improved diameter stenosis.
OCT-derived TCFAs have been recognized as distin-
guishing features of so-called vulnerable or rupture-
prone plaques [28]. Compared with TCFAs, ThCFAs had
less of a decrease in the lipid index, but had an increase
in diameter stenosis by follow-up period. The increase of
fibrous-cap thickness in ThCFAs was not significantly
different to that in TCFAs, while the decrease in lipid
core burden of ThCFAs was much smaller than that of
TCFAs. These findings might contribute to the differ-
ences between them in the changes in diameter stenosis,
and lumen dimensions, which are most likely one
process of statin-induced regression of ThCFAs; however,
the present study was conducted for only 12 months. It
Fig. 1 Comparisons of minimal lumen diameter in terms of OCT-derived plaque type. According to OCT-derived plaque types, plaques were classified into
TCFAs and ThCFAs, with or without macrophage, or microvessels, or cholesterol crystals. Minimal lumen diameter showed no significant differences
between groups
Fig. 2 Comparisons of diameter stenosis in terms of OCT-derived plaque type. At baseline, diameter stenosis were significantly worse in TCFAs (p = 0.021).
To compare the data at baseline and at follow-up in ThCFAs, we found that diameter stenosis was growing worse at follow-up (p = 0.014)
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remains unknown whether diameter stenosis of ThCFAs
would improve with a longer-term follow-up.
Limitations
First, it was inevitable that the retrospective study from a
clinical registry introduced a potential selection bias. Second,
because of the short duration and small size of population
of our study, the changes in CAG data did not correlated
with the changes in OCT measurements. Additional studies
with larger populations and longer term follow-up might be
needed. Third, the definition of OCT-derived TCFAs does
not correspond exactly with the histological definition of
TCFAs because OCTcannot measure the necrotic core size;
the macrophage infiltration, micro-vessels, cholesterol crys-
tals, thrombus, calcification, and disruption were not quanti-
fied in the present study. Finally, the general results of non-
culprit, lipid-rich plaques in this study cannot be applied to
other types of plaques.
Conclusion
We found that the lipid length on OCT and the lesion
length on CAG of lipid-rich plaques were closely corre-
lated; however, the other microstructural characteristics
measured by OCT and lumen dimensions by CAG were
not significantly correlated. After 12-month statin treat-
ment, we observed that microstructural characteristics
measured were significantly improved, while CAG-
derived lumen dimensions were not. Moreover, changes
in OCT measurements were not significantly correlated
with changes in CAG data induced by statin over time.
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